Highest-materiality recent filing
Metagenomi reports $160.8M cash, MGX-001 on track for IND in 4Q 2026
Cash, equivalents and marketable securities $160.8M as of Dec 31, 2025; runway through 4Q 2027.
Metagenomi renames to Metagenomi Therapeutics; hemophilia A program on track for IND in 2026
Name changed to Metagenomi Therapeutics, Inc. effective Jan 12, 2026; ticker MGX unchanged.
Metagenomi Q3: $184.1M cash, 25% workforce cut, CEO change, MGX-001 data positive
Cash, equivalents, and marketable securities $184.1M as of Sep 30, 2025; runway extended into Q4 2027.
Metagenomi reports Q2 2025 cash $205M; hemophilia A IND/CTA submission planned for 2026
Cash, cash equivalents and marketable securities of $205.0M as of June 30, 2025; runway expected into 2027.
Type II nuclease MG21-1 in single AAV achieved 69% protein knockdown in mouse motor cortex and 82% in brain via systemic delivery.
Metagenomi NHP hemophilia A study shows durable FVIII activity through 19 months; Q1 cash $226M
Hemophilia A NHP study: durable FVIII activity at therapeutically relevant levels through ~19 months; final FVIII levels 80%, 10%, 32%.
Metagenomi reports $248.3M cash; hemophilia A program on track for IND in 2026
Cash, cash equivalents, and marketable securities $248.3M as of Dec 31, 2024; runway into 2027.
FVIII activity sustained across 13-16.5 months in NHPs: 72%, 9%, 30% at 16.5 mo; integration freq 0.7-3.1%.
Metagenomi nominates MGX-001 DC for hemophilia A; reports $274.6M cash; Q3 expenses down
Nominated MGX-001 as first development candidate for hemophilia A; IND-enabling activities initiated, IND filing on track for 2026.
Metagenomi reports 12-month durable FVIII activity in preclinical hemophilia A study
All three NHPs showed durable FVIII activity at 12 months: 82%, 41%, and 9%.
Metagenomi declares MGX-001 DC for hemophilia A; cash $299.9M into 2027
Declared MGX-001 as lead development candidate for hemophilia A; 12-month NHP data accelerated to September 2024.
Metagenomi Q1 net loss $25.1M, cash $327.4M; regains base editing and RIGS rights from Moderna
Q1 net loss $25.1M ($1.19/share) vs $16.1M loss in Q1 2023; collaboration revenue $11.2M.
Mutually terminated 2021 Strategic Collaboration and License Agreement with Moderna as of April 26, 2024.
Metagenomi reports FY2023 net loss of $68.3M; Hemophilia A NHP proof of concept achieved
Net loss $68.3M in FY2023; collaboration revenue $44.8M, up from $17.2M in 2022.
On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the “Board”) of Metagenomi Therapeutics, Inc. (the “Company”) of his resignation from his position as a member of the Board, effective as of June 9, 2026.
appointed Eric Bjerkholt to serve as a director of the Board, each effective as of January 27, 2025
Max materiality 0.80 · Median 0.65 · Most common event other_material